Psoriasis
Conditions
Keywords
PPT, topical, psoriasis
Brief summary
The aim of the exploratory study is to compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT).
Interventions
DRUGLAS41004
once daily, topical, 100 microgram
DRUGreference
once daily, 100 microgram
Sponsors
Sciderm GmbH
Almirall, S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Male or female patients between 18 and 75 years of age with a diagnosis of stable plaque-type psoriasis (psoriasis vulgaris) for at least 12 months * Psoriatic plaques that are suitable to be defined as target area lesions by the following criteria: oPsoriatic plaques must be located on the trunk and/or extremities. Plaques that are located on the head (incl. scalp), palms, sole of the feet, intertriginous or genitoanal areas are not suitable as target areas * Comparable psoriatic plaques with at least 2 in each score (range 0-4) for the three distinct signs: scaling, erythema and induration * No more than 3 points difference in total score (= sum of scores for scaling, erythema and induration; Range 0-12) of the chosen comparable psoriatic plaques * Enough surface area to the psoriatic plaque to define eight clearly distinguishable (minimum distance between test areas: 1cm) test areas of at least 1 cm² size - Effective contraceptive methods for the duration of the study and for the 4 weeks after study drug discontinuation, for a patient of childbearing potential. Key
Exclusion criteria
* Too small a body surface area covered with psoriasis plaques that meet the specified inclusion criteria * Any condition that may interfere with the study assessments or ultrasound measurements of the skin and/or may have an influence on the skin immune response (incl. open wounds) * Current diagnosis of guttate, erythrodermic or pustular psoriasis * Patients who have received any topical anti-psoriatic drug in the test area within the last 2 weeks before treatment with the IMP. * Patients who have received topical products in the test area containing DEET (N,N-diethyl-m-polyamide), a common component of insect repellent products within 1 week before treatment with the IMP. * Patients who have received systemic biologics within the last 6 months before treatment with the IMP or any systemic antipsoriatic treatment (corticosteroids, ciclosporin, methotrexate, fumaric acid esters, acitretin etc)within the last 3 months before treatment with the IMP. * Significant skin diseases other than plaque-type psoriasis (psoriasis vulgaris), including but not limited to: skin disease due to tuberculosis or syphilis, rosacea, perioral dermatitis, acne vulgaris, skin atrophy, striae distensae, increased fragility of skin blood vessels, ichthyosis, ulcers, wounds and reaction after vaccination * Significant skin infections (including but not limited to: herpes, varicella, mycotic skin infections, bacterial skin infections or parasitic skin infections) * Excessive sunlight exposure within 28 days prior to study entry and during the conduct of the study * Usage of any topical formulation (incl. cosmetics, emollients, etc) on the designated target areas during the course of the study * Vitamin A intake \> 15,000 IU/day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease in thickness of infiltration | Day 1 (baseline) vs day 15 day (final) | measurement will be performed by ultrasound, comparing data from baseline (day1) vs end of trial (day15) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in clinical score | day 1 (baseline) vs day 15 (final) | scoring of total symptom score (0 - 12)will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
| Change in erythema score | day1 (baseline) vs day 15 (final) | scoring of erythema (0-4) will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
| Change in Induration score | day 1 (baseline) vs day 15 (final) | scoring of induration (0-4) will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
| Change in Scaling score | day 1 (baseline) vs day 15 (final) | scoring of scaling (0-4) will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
Countries
Germany
Outcome results
None listed